Ptc Therapeutics (PTCT) Retained Earnings (2012 - 2026)

Ptc Therapeutics' Retained Earnings history runs 15 years deep, the most recent figure standing at -$2.9 billion for Q2 2026.

• In Q2 2026, Retained Earnings fell 1.35% year-over-year to -$2.9 billion; the TTM figure through Jun 2026 stood at -$2.9 billion (down 1.35% YoY), while the FY2025 annual figure was -$3.0 billion, up 18.72% from the prior year.
• Retained Earnings for Q2 2026 stood at -$2.9 billion, up from -$3.0 billion in the prior quarter.
• The five-year high for Retained Earnings was -$2.2 billion in Q1 2022, with the low at -$3.6 billion in Q4 2024.
• The 5-year median for Retained Earnings is -$2.9 billion (2025), against an average of -$3.0 billion.
• The sharpest annual moves came in 2022 and 2025: Retained Earnings plunged 225.12% in 2022, then gained 20.99% in 2025.
• Ptc Therapeutics' Retained Earnings stood at -$2.7 billion in 2022, then slipped by 23.58% to -$3.3 billion in 2023, then retreated by 11.06% to -$3.6 billion in 2024, then gained by 18.72% to -$3.0 billion in 2025, then climbed by 2.72% to -$2.9 billion in 2026.
• Business Quant data shows PTCT's Retained Earnings at -$2.9 billion in Q2 2026, -$3.0 billion in Q1 2026, and -$3.0 billion in Q4 2025.